Because Oct4 and EpCAM were significantly related to prognosis in univariate analyses, we combined Oct4 and EpCAM to investigate their prognostic significance. The patients with both Oct4 and EpCAM low expressions were subsequently enrolled into double low expressions group (26.8%, 101/377) and other patients were in control group (73.2%, 276/377). Finally, out of 325 patients in survival analyses, 93 (28.6%) patients in Oct4-EpCAM double low expression group had significantly better prognosis than 232 (71.4%) patients in control group in Kaplan-Meier analysis (p<0.001) (Figure 7). Multivariate survival analyses indicated that age (p=0.036, HR=1.259, 95%CI [1.016-1.561]), Oct4-EpCAM expression (p=0.035, HR=1.485, 95%CI [1.028-2.145]) and TNM stage (p<0.001, HR=2.133, 95%CI [1.720-2.646]) were independent prognostic factors in IHC.